Bulk Pharmaceutical API Sources for PASIREOTIDE PAMOATE

Bulk Pharmaceutical API Sources for PASIREOTIDE PAMOATE

Vendor	Vendor Homepage	Vendor Sku	API Url
Clearsynth		CS-O-15480
MuseChem		I008561
MedChemexpress MCE		HY-108768
AbaChemScene		CS-0031013
THE BioTek		bt-278882

Pasireotide Pamoate Bulk API Sourcing Landscape

Last updated: February 19, 2026

This report analyzes the current landscape of bulk active pharmaceutical ingredient (API) sourcing for pasireotide pamoate, a somatostatin analog used in treating Cushing's disease and acromegaly. The analysis focuses on key suppliers, manufacturing capabilities, regulatory compliance, and potential supply chain vulnerabilities.

Who Are the Primary Manufacturers of Pasireotide Pamoate API?

Several contract manufacturing organizations (CMOs) and specialized API producers are identified as potential suppliers of pasireotide pamoate API. These entities possess the necessary technical expertise and manufacturing infrastructure to produce complex peptide APIs like pasireotide pamoate.

• Lonza: A significant player in peptide API manufacturing, Lonza has a strong track record in producing complex molecules for pharmaceutical clients. Their capabilities include solid-phase peptide synthesis (SPPS) and solution-phase synthesis, adaptable to various peptide structures. [1] Lonza operates multiple cGMP-compliant manufacturing sites globally.
• Bachem: Specializing in peptide and oligonucleotide synthesis, Bachem is a well-established API supplier with extensive experience in producing complex peptide APIs. They offer custom synthesis services and have demonstrated capacity for large-scale production of peptides. [2] Bachem's facilities adhere to strict regulatory standards.
• AmbioPharm: This company focuses on custom peptide synthesis and cGMP manufacturing of peptide APIs. AmbioPharm has expertise in producing complex peptides and has experience in scaling up production processes to meet commercial demands. [3] Their US-based facilities are FDA-inspected.
• Peptides International: While often known for research-grade peptides, Peptides International also offers custom synthesis and cGMP manufacturing services for API production. Their capabilities include handling complex peptide sequences and modifications. [4]
• Other Potential Suppliers: The generic API market is dynamic. Companies such as Novavax (through its acquisition of Contract Pharmaceuticals Limited), and several Chinese and Indian API manufacturers with strong peptide synthesis capabilities, may also be emerging or potential suppliers, though specific public data on their pasireotide pamoate production is less readily available.

Table 1: Key API Manufacturers with Peptide Synthesis Capabilities

Manufacturer	Specialization	cGMP Compliance	Notes
Lonza	Peptide API Manufacturing	Yes	Global sites, expertise in complex peptides.
Bachem	Peptide & Oligonucleotide Synthesis	Yes	Extensive experience, large-scale production capacity.
AmbioPharm	Custom Peptide Synthesis, cGMP API Manufacturing	Yes	US-based, FDA inspected, scalable peptide production.
Peptides International	Custom Synthesis, cGMP API Manufacturing	Yes	Handles complex sequences and modifications.

What Are the Manufacturing Considerations for Pasireotide Pamoate API?

The production of pasireotide pamoate involves intricate chemical synthesis and purification steps. Key manufacturing considerations include:

• Synthesis Route Complexity: Pasireotide pamoate is a synthetic somatostatin analog. Its synthesis typically involves multiple peptide coupling steps, potentially employing solid-phase peptide synthesis (SPPS) or solution-phase methods. The pamoate salt formation adds an additional step requiring careful control of reaction conditions and stoichiometry to ensure purity and yield. [5]
• Chiral Purity: Pasireotide has specific stereochemistry crucial for its biological activity. Ensuring high chiral purity throughout the synthesis is paramount. This necessitates the use of stereospecific reagents and rigorous analytical controls.
• Impurity Profiling: Identifying, characterizing, and controlling process-related impurities and degradation products is critical for API quality and patient safety. Regulatory agencies require comprehensive impurity profiles. [6]
• Scale-Up Challenges: Transitioning from laboratory-scale synthesis to commercial manufacturing can present significant challenges in maintaining reaction efficiency, yield, and purity. Process optimization and robust engineering controls are essential.
• Pamoate Salt Formation: The pamoate salt formation requires specific conditions to ensure crystalline structure, particle size distribution, and stability. These physical characteristics can impact downstream formulation and bioavailability.
• Stability: Pasireotide pamoate, like many peptide APIs, can be susceptible to degradation. Stability studies under various conditions are necessary to establish appropriate storage conditions and shelf life.

What Are the Regulatory Requirements for API Manufacturing?

Manufacturing pasireotide pamoate API must comply with stringent global regulatory standards to ensure product quality, safety, and efficacy.

• Current Good Manufacturing Practices (cGMP): All API manufacturing facilities must adhere to cGMP regulations as stipulated by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and Japan's Pharmaceuticals and Medical Devices Agency (PMDA). This includes robust quality management systems, process validation, equipment qualification, and detailed record-keeping. [7]
• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies. A DMF contains confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. These filings allow regulatory agencies to review the API manufacturing information without disclosing proprietary details to the drug product applicant. [8]
• ICH Guidelines: The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) provides harmonized guidelines that are essential for API development and manufacturing. Key guidelines include ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients), ICH Q11 (Development and Manufacture of Drug Substances), and ICH Q3A/B/C/D (Impurities). [9]
• Quality Agreements: Drug product manufacturers must establish comprehensive quality agreements with their API suppliers. These agreements define the responsibilities of each party regarding quality control, change management, batch release, and regulatory compliance.
• Site Inspections: Regulatory agencies conduct periodic inspections of API manufacturing sites to ensure ongoing compliance with cGMP. Successful inspections are critical for continued supply.

What Are the Potential Supply Chain Risks and Mitigation Strategies?

The supply chain for complex APIs like pasireotide pamoate carries inherent risks. Identifying and mitigating these risks is crucial for ensuring consistent drug product availability.

• Single-Source Dependency: Relying on a single API manufacturer can create significant vulnerability. A disruption at that facility (e.g., regulatory action, natural disaster, production issues) could halt drug product manufacturing.
  • Mitigation: Qualify and maintain relationships with at least two independent API suppliers. Diversifying the supplier base reduces reliance on a single entity.
• Geopolitical Instability and Trade Restrictions: Global supply chains are susceptible to geopolitical events, trade wars, and tariffs that can impact raw material sourcing, manufacturing costs, and transportation.
  • Mitigation: Conduct geopolitical risk assessments of key supplier locations. Explore sourcing from diverse geographic regions. Maintain inventory buffers for critical raw materials.
• Raw Material Availability and Quality: The synthesis of pasireotide pamoate relies on specific amino acids, coupling reagents, solvents, and other chemical intermediates. Disruptions in the supply or quality issues with these raw materials can impact API production.
  • Mitigation: Implement robust supplier qualification programs for all raw material suppliers. Conduct thorough incoming raw material testing. Establish second-source qualifications for critical raw materials.
• Intellectual Property (IP) Landscape: While the originator's patent for pasireotide pamoate will expire, navigating the IP landscape for manufacturing processes and intermediates is essential. Generic manufacturers must ensure their processes do not infringe existing patents.
  • Mitigation: Conduct thorough freedom-to-operate (FTO) analyses for proposed manufacturing routes. Secure appropriate licenses if necessary.
• Logistics and Transportation: The global transport of APIs requires specialized handling, temperature control, and adherence to customs regulations, increasing the risk of delays or product damage.
  • Mitigation: Partner with experienced pharmaceutical logistics providers. Utilize temperature-controlled shipping and real-time tracking.
• Regulatory Changes: Evolving regulatory requirements in different markets can necessitate changes in manufacturing processes or documentation, potentially impacting supply timelines and costs.
  • Mitigation: Maintain proactive engagement with regulatory consultants and industry groups to stay abreast of regulatory changes. Implement flexible manufacturing processes that can adapt to evolving requirements.

What is the Intellectual Property (IP) Landscape for Pasireotide Pamoate API Manufacturing?

The primary patent protecting pasireotide pamoate as a therapeutic agent has expired or is nearing expiration in key markets, opening opportunities for generic competition. However, specific manufacturing processes or crystalline forms might still be protected.

• Originator Patents: The original patents covering pasireotide itself and its therapeutic uses have been instrumental in establishing market exclusivity for the innovator product (e.g., Signifor® by Novartis). Expired or expiring composition of matter and use patents are the primary drivers for generic API development. [10]
• Process Patents: Manufacturers may develop and patent novel or improved methods for synthesizing pasireotide pamoate API. These process patents can offer a degree of exclusivity for a specific manufacturing route, even after the composition of matter patent has expired. [11] Generic API manufacturers must carefully evaluate existing process patents to ensure their chosen synthesis route does not infringe.
• Polymorph Patents: Different crystalline forms (polymorphs) of an API can have distinct physical properties, such as solubility and stability, affecting bioavailability. Patents may be granted for specific, advantageous polymorphs of pasireotide pamoate.
  • Example: While specific polymorph patents for pasireotide pamoate are not widely detailed in public databases, it is a common strategy to seek patent protection for advantageous crystalline forms of established drugs. Generic manufacturers would need to ensure their API production yields a non-infringing polymorph or one that is off-patent.
• Freedom-to-Operate (FTO): Companies intending to manufacture or supply pasireotide pamoate API must conduct comprehensive FTO analyses. This involves searching and analyzing granted patents and pending applications globally to identify any potential IP barriers to their intended commercial activities. [12]

Conclusion

The global supply of pasireotide pamoate API is supported by a network of specialized peptide manufacturers and CMOs capable of producing complex molecules under cGMP conditions. Key suppliers like Lonza, Bachem, and AmbioPharm possess the technical expertise and regulatory track record. However, potential API purchasers must diligently assess manufacturing complexities, regulatory compliance, and critically, implement robust risk mitigation strategies for the supply chain. Diversifying suppliers, securing raw materials, and conducting thorough IP freedom-to-operate analyses are paramount for ensuring a stable and compliant supply of pasireotide pamoate API in anticipation of market shifts.

Key Takeaways

• Several established CMOs and peptide specialists, including Lonza, Bachem, and AmbioPharm, are capable of manufacturing pasireotide pamoate API under cGMP conditions.
• The synthesis of pasireotide pamoate is complex, requiring control over chiral purity, impurity profiles, and specific salt formation conditions.
• Adherence to global cGMP regulations, comprehensive DMF filings, and ICH guidelines are mandatory for API suppliers.
• Supply chain risks include single-source dependency, geopolitical instability, raw material availability, IP limitations, and logistics.
• Mitigation strategies involve supplier diversification, rigorous raw material qualification, FTO analyses, and experienced logistics partnerships.
• While originator patents for pasireotide are expiring, process and polymorph patents may still present IP considerations for generic API manufacturers.

Frequently Asked Questions

What is the typical lead time for custom synthesis of pasireotide pamoate API from a new supplier?

Lead times for custom synthesis of complex peptide APIs can range from 6 to 18 months, depending on the supplier's current capacity, the complexity of the synthesis route, and the required scale. This period includes process development, optimization, validation, and commercial batch manufacturing.

How do regulatory agencies audit API manufacturing sites?

Regulatory agencies conduct routine and For-Cause inspections of API manufacturing facilities. These audits typically involve a comprehensive review of quality management systems, batch records, equipment calibration and maintenance, validation reports, personnel training, environmental monitoring, and adherence to cGMP principles.

What are the critical quality attributes (CQAs) for pasireotide pamoate API?

Critical Quality Attributes for pasireotide pamoate API include assay (potency), purity (related substances, residual solvents, heavy metals), identity, chiral purity, water content, particle size distribution, and polymorphic form, as these directly impact the safety and efficacy of the finished drug product.

How is the stability of pasireotide pamoate API typically assessed?

Stability is assessed through long-term and accelerated stability studies conducted according to ICH Q1A(R2) guidelines. Samples are stored under controlled temperature and humidity conditions, and tested at predetermined intervals for CQAs to establish shelf life and recommended storage conditions.

What are the key differences between producing pasireotide API and pasireotide pamoate API?

The primary difference lies in the final salt formation step. Pasireotide API is the free peptide or a different salt. Pasireotide pamoate API involves an additional chemical step to form the pamoate salt, which requires specific reaction conditions, stoichiometry, and crystallization procedures to achieve the desired physical and chemical properties of the final API.

Are there any specific analytical methods mandated for pasireotide pamoate API release testing?

While specific methods are proprietary to manufacturers and detailed in DMFs, typical analytical methods for peptide API release testing include High-Performance Liquid Chromatography (HPLC) for assay and purity, Mass Spectrometry (MS) for identity and impurity characterization, Karl Fischer titration for water content, and Powder X-ray Diffraction (PXRD) for polymorphic form.

Citations

[1] Lonza. (n.d.). Peptide manufacturing. Retrieved from https://www.lonza.com/services/manufacturing-services/peptide-manufacturing

[2] Bachem. (n.d.). Peptides for API. Retrieved from https://www.bachem.com/products-and-services/peptides-for-api/

[3] AmbioPharm. (n.d.). cGMP Peptide API Manufacturing. Retrieved from https://ambiopharm.com/services/peptide-api-manufacturing/

[4] Peptides International. (n.d.). Custom Peptide Synthesis. Retrieved from https://www.pepnet.com/ (Note: While Peptides International's main site focuses on research peptides, their corporate information often indicates cGMP capabilities. Direct access to specific API services may require direct inquiry.)

[5] U.S. Food and Drug Administration. (n.d.). CMC Information for Manufacturers. Retrieved from https://www.fda.gov/drugs/guidance-compliance-regulatory-information/chemistry-manufacturing-and-controls-cmc-information-manufacturers

[6] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2009). ICH Harmonised Tripartite Guideline Impurities: Guideline for Residual Solvents Q3C(R4).

[7] U.S. Food and Drug Administration. (2022). 21 CFR Part 210 – Current good manufacturing practice in manufacturing, processing, packaging, or holding of drugs; general.

[8] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from https://www.fda.gov/drugs/drug-master-files

[9] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2009). ICH Harmonised Tripartite Guideline Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients Q7.

[10] Novartis AG. (2014). US Patent 8,642,543 B2: Pasireotide and its use in treating pituitary tumors.

[11] World Intellectual Property Organization. (n.d.). Patent Scope Search. Retrieved from https://patentscope.wipo.int/ (This is a general search portal; specific process patents would require targeted searches.)

[12] World Intellectual Property Organization. (n.d.). PCT Application Search. Retrieved from https://pct.wipo.int/ (This is a general search portal; specific process patents would require targeted searches.)